William G. James

William G. James

William G. James

Bill James, a partner in Goodwin's IP Litigation Group, has more than 18 years experience in patent litigation related to pharmaceutical and biotechnology products. He has significant experience with Hatch-Waxman litigations, representing both plaintiffs and defendants, including first-to-file cases and multi-defendant ANDA drug challenges, and has participated in several appeals before the U.S. Court of Appeals for the Federal Circuit.

Dr. James also advises pharmaceutical and biotechnology companies on freedom-to-operate, due diligence, licensing and prosecution issues, and has experience coordinating worldwide patent litigation strategies and providing strategic counseling on biosimilar products.

Professional Activities

Dr. James is a member of the American Bar Association, the New York Intellectual Property Law Association and the American Intellectual Property Law Association.

Professional Experience

Prior to joining Goodwin in 2014, Dr. James was a partner at Kenyon & Kenyon in Washington, D.C., where he served on the firm’s Management Committee.

Areas of Practice


Dr. James’ recent work includes representing:

  • Teva Pharmaceuticals and Yeda Research and Development, in consolidated Hatch-Waxman litigations concerning proposed generic equivalents to Teva's blockbuster multiple sclerosis drug Copaxone®. Following trial, the court ruled that Teva and Yeda's nine patents in suit were valid, enforceable and infringed by the proposed generic products of defendants Sandoz/Momenta Pharmaceuticals and Mylan/Natco Pharma. Teva Pharmaceuticals USA v. Mylan Pharmaceuticals and Teva Pharmaceuticals USA v. Sandoz (S.D.N.Y.)
  • Ben Venue Laboratories in Hatch-Waxman litigation brought by Helsinn and Roche in the District of Delaware on patents concerning the drug product Aloxi® (palonosetron HCl).
  • Ben Venue Laboratories in Hatch-Waxman litigation brought by Spectrum Pharmaceuticals in the District of Nevada on patents concerning the drug product Fusilev® (levoleucovorin).
  • Teva Pharmaceuticals at trial in the Southern District of New York in a Hatch-Waxman litigation brought by Gilead Sciences on patents concerning the drug product Emtriva® (emtricitabine).
  • Intervet in biotechnology patent litigation brought against Intervet's Circumvent® porcine circovirus vaccine. Dr. James represented Intervet at Markman hearing. Intervet obtained a favorable Markman ruling leading to summary judgment of non-infringement and favorable settlement. Intervet v. Merial Limited et al. (D.D.C.)



J.D., 1996
New York University School of Law
D.V.M., Physiology, 1989
Oklahoma State University



New York
District of Columbia
U.S. Patent and Trademark Office (USPTO)


U.S. District Court for the Eastern District of New York
U.S. District Court for the Southern District of New York
U.S. Court of Appeals for the Federal Circuit
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers